Primary mediastinal B-cell lymphoma (PMBL) is an aggressive extranodal B-cell non-Hodgkin's lymphoma with specific clinical, histopathological and genomic features. To characterize further the genotype of PMBL, we analyzed 37 tumor samples and PMBL cell lines Med-B1 and Karpas1106P using arraybased comparative genomic hybridization (matrix-or array-CGH) to a 2.8k genomic microarray. Due to a higher genomic resolution, we identified altered chromosomal regions in much higher frequencies compared with standard CGH: for example,
Introduction
Primary mediastinal B-cell lymphoma (PMBL) is a distinct clinicopathological entity in the WHO classification of nonHodgkin's lymphomas (ICD-O: 9679/3). 1 Due to the location and morphologic characteristics, PMBL is a unique lymphoma subset that probably derives primarily from asteroid thymic B cells. [2] [3] [4] [5] PMBL is positive for CD19, CD20, CD45, and often CD30, CD79a, CD11c, CD23 and negative for CD10 and CD21. 6 Highly characteristic is a lack of immunoglobulin surface antigen and a missing expression of major histocompatibility complex (MHC) class I and II molecules. 7, 8 More recently, the expression of BSAP, BOB1, OCT2, PAX5 and PU1 was added to the spectrum typical of PMBL features. 9 Genetically, a pattern of highly recurrent karyotype alterations with the hallmark of chromosomal gains of the subtelomeric region of chromosome 9 supported the concept of a unique disease entity that distinguishes PMBL from other B-cell nonHodgkin's lymphomas. 10, 11 Together with less specific gains on 2p15 and frequent mutations of the SOCS1 gene, a notable genomic similarity to classical Hodgkin's lymphoma was observed. [12] [13] [14] The genetic overlap of the two entities has been supported recently by the results of mRNA gene expressions studies. [15] [16] [17] A number of critical genes, such as JAK2, REL, cMYC, MAL, PDL, SOCS1 and CDKN2A, have been discussed to be involved in the pathogenesis of PMBL. However, the cascade of oncogenic events leading to PMBL is still elusive. The detailed delineation of aberrant chromosomal regions using high-resolution, microarray-based genomic techniques [18] [19] [20] [21] [22] [23] allowing candidate gene identification provides a suitable tool for clarifying the genetic causes of this disease.
Materials and methods
Thirty-seven fresh, frozen tumor samples of PMBL were included in the study. Histopathological diagnosis was based on morphologic and immunohistochemical criteria according to the WHO classification of malignant lymphomas 1 by two expert hematopathologists (PM and TFEB). A total of 22 male and 15 female patients were analyzed. The median age was 36 years (for more details see Table 1 ). For all cases, chromosomal comparative genomic hybridization (cCGH) data along with selected fluorescent in situ hybridization and cytogenetic data were published earlier. 11, 12 However, for most cases of the analyzed series, sufficient material for systematic mRNA expression analysis was not available any more.
For the construction of a 2800 targets comprising genomic microarray, a genome-wide distributed core set of DNA fragments was selected out of the previously published, acknowledged 'GoldenPath' clone set. The targets were set at intervals of approximately 2 Mb across the entire human genome (alternating clones of the GoldenPath; in total 1500 clones). This compilation was supplemented with a set of 600 DNA fragments, which focuses critical regions of B-cell neoplasms as detected by previous cytogenetic studies, for example, 2p13, 9p24 or 11q13. Finally, 699 DNA targets specific for, for example, proto-oncogenes or tumor suppressor genes with discussed pathogenetic relevance in B-cell nonHodgkin's lymphoma were added. The final chip contained 2799 clones. A list of all clones with respective physical mapping information is given in Supplementary Table S1. DNA preparation of all bacterial artificial chromosome and P1-derived artificial chromosome clones and subsequent sequential degenerative oligonucleotide primer-mediated DNA amplification was performed as described by Fiegler et al., 24, 25 with three minor modifications of the original protocol. A detailed description of the applied PCR procedures is listed in the supplement. The PCR products were spotted onto Corning CMT-Gaps II glass slides using an Omnigrid microarrayer (Gene Machines, San Carlos, CA, USA). DNA labeling, hybridization and data acquisition were performed as described previously. [21] [22] [23] 25 Fluorescence ratios were obtained using an Axon 4000 B dual laser scanner, computed as log2 ratios and normalized based on the linear clone set of 1500 clones (for details, see Schwaenen et al.
21
), excluding X and Y clones for normalization. Thereupon, the ratios of two reverse color experiments were averaged. The diagnostic cutoff level for each individual experiment was determined by calculating the mean and subsequently using plus/minus three times the standard deviation of all clones from chromosomes 1-22. Additionally, those regions were scored as aberrant, whose signal ratios narrowly missed the threshold criteria but were deviated unidirectionally in at least three adjacent targets. This was done to take into account aberrations of tumors with lower tumor cell fractions (for more details see Schwaenen et al. 21 ). The cutoff value for the detection of DNA amplifications was determined by repetitive hybridizations of normal male vs normal female DNA. Due to the ratios for clones mapping to chromosome X in these experiments, the cutoff ratio for amplifications was 1.6 (for details see Wessendorf et al. 20 ). All data sets were carefully reviewed for frequently affected chromosomal sites of physiologic copy number polymorphisms (CNP). Therefore every clone on the array was compared with the 'Database of Genomic Variants' (http://www.projects.tcag.ca/variation/). 26, 27 Clones and sites located in regions with known copy number polymorphisms are marked in Figure 1 and in Supplementary  Table S1 , enabling a conservative evaluation of the array data. Alterations, which entirely covered CNPs, were excluded from the evaluation (for example, 5p11, 7q35, 14q32 and 15q11). For the present study, the Y chromosome was excluded from the analysis and the X chromosome was only evaluated with regard to DNA amplifications, since in all experiments, gender difference between tumor DNA and control DNA was used to monitor the integrity of each experiment.
Results
In 33 of the 37 (89%) tumor samples, a total of 199 chromosomal imbalances were detected by array-CGH. The median number of aberrations was 5 (range ¼ 0-19). A total of 130 chromosomal gains and 69 losses were identified. In four patients, no aberrations were found. Chromosomal gains in more than 10% of all cases (nX4) were detected on 9p24
, 1q and 21q (both n ¼ 4). Genomic losses affected preferably 15q (n ¼ 6), 4q and 13q14 (both n ¼ 5), and 8p, 6p21, 11q13 and 14q32 (all n ¼ 4). Nineteen high-level DNA amplifications were identified by array-CGH localizing to (i) the previously described regions 2p15 (n ¼ 4); 9p24 (n ¼ 4) and X (n ¼ 3; see also annotations for Table 4 in which an overview of all DNA amplifications is given) and (ii) to the novel locations 1p, 2q, 5q and 7p, however, all of the latter represented solitary aberrations. For aberrations which were present in at least 10% of all cases 
Discussion
Applying array-CGH, we aimed to identify previously unknown chromosomal imbalances and to further characterize those regions that have been described previously. Using the 2.8k chip, we found approximately three times as much genomic losses in comparison to previous cCGH analysis (69 vs 25). 10, 11 The higher frequency of these losses was caused by the presence of small-sized (o10 Mb) intrachromosomal deletions (for example, 6p21.3, 3p23-p25, 11q13.3) that were not detectable by the cCGH approach. The total number of genomic gains corresponded well to cCGH (130 vs 135). Imbalances affecting large sections (410 Mb) or the entire arm of chromosomes 1-15 were detected by both techniques. Interestingly, for chromosomes 16 and 22, notably less chromosomal gains were found by array-CGH (6 vs 18). In our hands, these discrepancies most likely reflect a higher reliability of array-CGH for these chromosomes. This technique scores the signal ratios of solitary DNA fragments that serve as an internal control for the aberration scoring of respective up-and downstream-located targets. Thus, by separation of defined chromatin segments, array-CGH overcomes a diagnostic limitation of conventional CGH, especially for those critical chromosomes on which repeatedly false-positive cCGH signals have been observed in the past. Moreover, taking advantage of the array's resolution, an elevated number of distinct high-level DNA amplifications (19 vs 8) were identified. Novel amplifications occurred as small-sized amplicons of regions most of which have not been discussed in lymphoma pathogenesis previously (see Table 4 ).
For 17 genomic localizations, we were able to delineate minimal common regions. Affected regions and genes will be outlined in the context of molecular pathways with suspected pathogenetic relevance.
Constitutive activation of NF-kB
A constitutive activation of this nuclear transcription factor in PMBL has been demonstrated recently. 29 In this context, for 2p15, a markedly higher frequency of genomic gains/amplifications was identified using array-CGH when compared to cCGH (51 vs 20%). This is in line with recent data obtained by fluorescent in situ hybridization analysis demonstrating the presence of 2p15 gains up to 75%. 30 In our investigation, we observed a continuous transition between high-level amplifications and single copy gains. In all cases carrying amplifications (n ¼ 4), both REL and BCL11A were affected. For cases with lower copy number gains BCL11A was always covered, whereas REL was not part of the minimal consensus region. To validate further these findings, we compared the genomic status with immunohistochemical stainings for BCL11A and REL, which have been analyzed previously by Weniger et al. 30, 31 Complete data sets were available for 16/37 cases. In 10 of these 16 cases, genomic gains at 2p15 were observed using array-CGH. In nine of these samples, a concomitant elevated (X30%) nuclear protein accumulation for REL and/or BCL11A were detected. In two cases with no aberrations on the 2p15 locus, immunohistochemistry revealed a missing or only slight detection of the respective proteins and in the remaining four cases, protein detection of 430% was found despite a diploid genomic status. Confirming reports by Weniger et al., there was no straight correlation of the genomic status herein measured by array-CGH and the relative mRNA transcript levels of BCL11A and REL (real-time quantitative PCR).
As a second putative chromosomal region involved in NF-kB pathway activation, we observed a DNA amplification/gain, affecting chromosomal band 1p22 covering the BCL10 gene. This protein forms a caspase recruitment domain, and has been shown to activate NF-kB. BCL10 is reported to interact with other caspase recruitment domains containing proteins including caspase recruitment domain9, 10, 11 and 14, which are believed to function as upstream regulators in NF-kB signaling. Moreover, BCL10 forms a complex with MALT1, which leads to a synergistic activation of NF-kB. 32 In one of eight cases with MALT1 affecting gains on 18q21, a coincidental 1p22 gain was found. We therefore propose to further consider these chromosomal regions in the analysis of the genetic causes of constitutive NF-kB activation in PMBL. Abbreviations: CGH, comparative genomic hybridization; PMBL, primary mediastinal B-cell lymphoma. For the recurrent amplicons on 2p, 7q and 9p percentages and consensus regions and their flanking clones, for singular events only flanking clones are listed. a Although chromosome X was not included in the numerical analysis, for high-level amplifications, the localizations of the amplicon peaks in the cases with known amplicons (chromosomal CGH) was possible due to their circumscript high amplitudes (42.5). No amplicons were found in the cell lines Med-B1 and Karpas1106P.
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Defective surface expression of major histocompatibility complex molecules
Losses of the MHC class I/II genes on 6p are among the most frequent deletions in aggressive B-cell non-Hodgkin's lymphoma. 33 Using array-CGH, in four cases, a distinct 3.9 Mb deletion on 6p21 was identified, which covers the majority of genes forming up the MHC (human leukocyte antigen class I and/or II). Interestingly, a recent investigation in PMBL has shown a worse outcome in patients where MHC class II genes were downregulated on mRNA and protein expression level. However, a deletion of the respective genomic region was not suspected to be causal of these gene dysregulations. 34 In contrast to other Bcell non-Hodgkin's lymphoma entities expressing MHC class I/II surface molecules, alterations of these molecules might provide PMBL cells with an additional growth advantage by escape from the immune system, a mechanism which has been extensively studied in various solid tumor entities and cell culture models. 13, 14 Summarizing these data, it still remains controversial whether MCH II gene deregulation in PMBL is attributable to genomic DNA copy number changes. Our data warrant further genomic analysis of 6p21 locus alterations in PMBL using, for example, oligonucleotide single nucleotide polymorphism array approaches in combination with gene expression data, as well as analysis of molecules associated with function of MHC class I/II such as b2-microglobulin and the invariant chain (li).
Impaired apoptosis by FAS-associated via death domain dysregulation
In eight cases, deletions on 8p or 11q13 affected genes involved in FAS-associated via death domain (FADD)-mediated apoptosis. Four cases had a loss of the 8p arm covering TNRSF that encodes a receptor which is activated by tumor necrosis factor-related apoptosis-inducing ligand and also transduces apoptosis signal via FADD. Additionally, four cases harbored deletions on 11q13.3, directly involving FADD, whose protein builds the death-inducing signaling complex together with procaspase 8. Deletions of this latter region have not been described in the context of lymphomagenesis so far. Considering these data, a defective FADD-mediated apoptosis might add to an impaired physiological balance for cell proliferation and apoptosis in PMBL.
Altered T-cell response regulation and JAK/STAT pathway activation
Gain of the subtelomeric region of 9p was found to be the most frequent aberration detected with array-CGH. In the present study, the precise extension of this hallmark region for PMBL was narrowed down to 6.6 Mb with an interspersed recurrent high-level amplicon of approximately 1.6 Mb. This DNA amplicon covers 10 known genes and encompasses both, the tyrosin kinase JAK2 and also the T-cell response regulators PDL1 and PDL2. A disease-specific expression dysregulation of 9p24-localized genes has been demonstrated in previous differential gene expression studies where PDL2 has proven to be the strongest discriminator between PMBL and other diffuse large Bcell lymphoma (DLBCL) entities. 15 Our results confirm the involvement of these genes in a small commonly amplified region in PMBL. For the entire subtelomeric 6.6 Mb region on 9p, a total of 22 gene annotations (OMIM) (plus 30 hypothetical genes or functional unknown proteins) have been identified. For eight of these, an involvement in transcriptional processes or cell-cycle control (FOXD4, DMRT1, DMRT3, SMARCA2, GLIS, CDC37L1) or tumorigenesis (ANKRD15, UHRF2) has been reported. Thus, these genes should also be considered for further investigations of this region. Apart from numeric 9p alterations, coinciding with JAK2 mRNA overexpression, delayed degradation of phosphorylated JAK2 caused by mutations or deletions of the SOCS1 gene has recently been suggested to constitute an alternative mechanism promoting cell proliferation in PMBL. 35 Additionally, homozygous deletions of approximately 0.7 Mb covering SOCS1 and PIG7/LITAF have been described in the Karpas1106P cell line using array-CGH. 36, 37 In our array analysis, interstitial deletions on the chromosomal band 16q13.13 have not been identified; however, the critical region was not directly represented on the array (flanking DNA targets were localized approximately 1 Mb distance up-and 0.7 Mb downstream).
Others
For a number of previously analyzed regions, namely 8q24, 12q13, 13q14 and 18q21, we were able to suggest more precisely genomic extensions on the basis of their respective flanking DNA fragments. However, these regions still cover large chromatin segments (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) which are mostly in accordance with previous findings using CGH and fluorescent in situ hybridization.
In contrast, on 2q24, 3q27, 7q22 and 17p13 novel smallsized aberrant regions were identified, each covering a very limited number of coding sequences. A solitary DNA amplification has been identified on 2q24. Here, a consensus region of 10 Mb in size with co-amplification of the IL8RA/B genes has been detected in three additional cases. For these receptors, an involvement in chemokine-mediated tumor cell growth has been reported. Moreover, this receptor causes an interleukin-8-mediated angiogenetic effect. On 3q27, we delineated a 1 Mb consensus-gained region covering six genes including the transcriptional co-repressor BCL6, for which an important role in the pathogenesis of DLBCL by suppression of TP53 gene expression has been described. For the remaining genes, no involvement in tumorigenesis has been described so far. Gains on the long arm of chromosome 7 belonged to the most frequent aberrations (32%). A DNA amplification covering the CDK6 gene, which is important for cell-cycle G1 phase progression and G1/S transition, was identified proximally to a distinct 1.0 Mb consensus region of low copy gains. Within this region, only three genes without involvement in malignancy have been annotated. Finally, a subtelomeric 1.8 Mb region was identified on 17p13. This deletion contains the tumor suppressor gene ABR, frequently deleted in medulloblastoma and TUSC5, identified in lung cancer cell lines.
Conclusions
Our data set gives detailed karyotypic features of PMBL and genomically maps recurrent chromosomal consensus regions. Due to the improved resolution of array-CGH, the frequency and the exact delineation of known aberrations, as well as new recurrent aberrations were performed more exactly than by genomic screening methods in the past. Our findings of recurrent intrachromosomal imbalances and DNA amplifications point to genes and regions of genomic instability that ought to be considered in molecular pathogenetic analysis in PMBL.
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